Connect your AI

Artiva Biotherapeutics, Inc. ARTV Q4 2024 Annual earnings

Reported March 25, 2025 · Before market open

Diluted EPS-$0.66Beat by $0.05

EPS estimate-$0.71

Next report

Aug 5, 2026 (in a month)

EPS estimate-$0.64

Financials

Q4 2024

Income statement

Operating income-$18.3M-52.6%

Net income-$16.1M-34.1%

Balance sheet

Cash & equivalents$40.5M-24.7%

Total debt$14.4M-15.1%

Total equity$186.6M+215%

Total assets$209.6M+99.4%

Cash flow

Operating cash flow-$14.7M-37.2%

CapEx$64.0K-89.9%

Free cash flow-$14.7M-30.1%

Valuation & ratios

Valuation

as of 12/31/24

Market cap$244.84M—

Enterprise value$218.7M—

Returns & leverage

Debt / equity0.1×—

Current ratio15.4×+8.9×

Versus estimates

Diluted EPS

Q1 2026-$0.95Miss by $0.07 Q4 2025-$0.84Beat by $0.03 Q3 2025-$0.88Beat by $0.04 Q2 2025-$0.87Miss by $0.03 Q1 2025-$0.83Miss by $0.15

Q4 2024-$0.66Beat by $0.05

Ask the moment Artiva Biotherapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Harbor at dusk

Questions, answered.

When did Artiva Biotherapeutics, Inc. report Q4 2024 earnings?: Artiva Biotherapeutics, Inc. (ARTV) reported Q4 2024 earnings on March 25, 2025 before market open.
What were Artiva Biotherapeutics, Inc.'s Q4 2024 revenue and EPS?: Artiva Biotherapeutics, Inc. reported diluted EPS of $-0.66 for Q4 2024.
Did Artiva Biotherapeutics, Inc. beat estimates in Q4 2024?: EPS beat the consensus estimate of $-0.71 by $0.05.
Where can I find Artiva Biotherapeutics, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0000950170-25-043837) directly on SEC EDGAR. The filing index links above go to sec.gov.